Deciphera Pharmaceuticals, Inc. (DCPH)

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable m.

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines, and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of vimseltinib for the treatment of.

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Re.

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for vimseltinib, a colony stimulating factor 1 receptor (CSF1R), for the treatment of patients with tenosynovial giant cell tumor (TGCT), which is under development by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly-owned subsidiary of.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois,.

Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.

While the top- and bottom-line numbers for Deciphera Pharmaceuticals (DCPH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.60 per share a year ago.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS: DCPH) to ONO Pharmaceutical Co., Ltd. Under the terms of the proposed transaction, shareholders of Deciphera will receive $25.60 in cash for each share of Deciphera that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets.

NEW YORK , April 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) , relating to its proposed merger with ONO Pharmaceutical Co., Ltd.

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion.  Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion.  Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.

Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical. This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash.

MILWAUKEE , April 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Deciphera (NASDAQ: DCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with ONO. Click here to learn how to join the https://www.ademilaw.com/case/deciphera-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion.